Winslow Evans & Crocker Inc. increased its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 9.1% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 6,365 shares of the medical research company’s stock after acquiring an additional 529 shares during the period. Winslow Evans & Crocker Inc.’s holdings in Amgen were worth $1,096,000 at the end of the most recent reporting period.
Other large investors have also bought and sold shares of the company. TrimTabs Asset Management LLC lifted its stake in shares of Amgen by 88.9% in the first quarter. TrimTabs Asset Management LLC now owns 612 shares of the medical research company’s stock worth $100,000 after buying an additional 288 shares in the last quarter. Alpha Omega Wealth Management LLC lifted its stake in shares of Amgen by 19.0% in the first quarter. Alpha Omega Wealth Management LLC now owns 625 shares of the medical research company’s stock worth $103,000 after buying an additional 100 shares in the last quarter. Jackson Grant Investment Advisers Inc. lifted its stake in shares of Amgen by 0.6% in the first quarter. Jackson Grant Investment Advisers Inc. now owns 636 shares of the medical research company’s stock worth $104,000 after buying an additional 4 shares in the last quarter. American Beacon Advisors Inc. bought a new position in shares of Amgen in the first quarter worth approximately $106,000. Finally, Nelson Roberts Investment Advisors LLC bought a new position in shares of Amgen in the first quarter worth approximately $121,000. 78.10% of the stock is currently owned by institutional investors and hedge funds.
Several brokerages have recently issued reports on AMGN. Royal Bank Of Canada began coverage on shares of Amgen in a research note on Thursday, September 14th. They issued a “sector perform” rating and a $192.00 target price on the stock. Bank of America Corporation upped their target price on shares of Amgen to $210.00 and gave the stock a “buy” rating in a research note on Thursday. Oppenheimer Holdings, Inc. reiterated a “buy” rating and issued a $203.00 target price on shares of Amgen in a research note on Friday. Morgan Stanley reiterated an “overweight” rating and issued a $196.00 target price (up previously from $189.00) on shares of Amgen in a research note on Friday. Finally, Mizuho reiterated a “buy” rating and issued a $198.00 target price on shares of Amgen in a research note on Friday. Ten investment analysts have rated the stock with a hold rating, eleven have assigned a buy rating and two have issued a strong buy rating to the company. Amgen currently has an average rating of “Buy” and a consensus price target of $189.99.
Shares of Amgen Inc. (NASDAQ:AMGN) traded down 0.55% during mid-day trading on Friday, reaching $185.82. 2,239,269 shares of the company’s stock were exchanged. The company has a market capitalization of $135.59 billion, a PE ratio of 16.92 and a beta of 1.36. Amgen Inc. has a one year low of $133.64 and a one year high of $191.10. The company’s 50-day moving average price is $181.33 and its 200-day moving average price is $170.23. Amgen also was the target of some unusual options trading activity on Thursday. Investors bought 9,350 put options on the stock. This represents an increase of 239% compared to the average daily volume of 2,758 put options.
Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Tuesday, July 25th. The medical research company reported $3.27 EPS for the quarter, beating the consensus estimate of $3.11 by $0.16. Amgen had a net margin of 35.46% and a return on equity of 29.85%. The business had revenue of $5.81 billion during the quarter, compared to analysts’ expectations of $5.67 billion. During the same period in the previous year, the business posted $2.84 EPS. The business’s quarterly revenue was up 2.1% compared to the same quarter last year. On average, equities analysts expect that Amgen Inc. will post $12.58 earnings per share for the current year.
The firm also recently disclosed a quarterly dividend, which was paid on Friday, September 8th. Shareholders of record on Thursday, August 17th were paid a dividend of $1.15 per share. This represents a $4.60 annualized dividend and a yield of 2.48%. The ex-dividend date was Tuesday, August 15th. Amgen’s payout ratio is 41.93%.
WARNING: This article was reported by Transcript Daily and is owned by of Transcript Daily. If you are accessing this article on another domain, it was illegally stolen and republished in violation of United States and international trademark and copyright laws. The original version of this article can be accessed at https://transcriptdaily.com/2017/10/08/winslow-evans-crocker-inc-boosts-position-in-amgen-inc-amgn.html.
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.